Clinical Trial Update: Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating efficacy and safety of Glassia for new onset type 1 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Glassia (alpha-1 proteinase inhibitor)

Snippet

Sponsor: Kamada, Ltd. | Conditions: New Onset Type-1 Diabetes | Phase 2 | Status: COMPLETED